Fig. 1

Dapagliflozin causes increases in rates of hepatic ketogenesis and glucose production due to extracellular volume depletion. a–d Plasma glucose, bicarbonate, acetoacetate, and β-OHB concentrations. In panel c, n = 7 dapagliflozin-treated and n = 6 in all other groups. e, f Whole-body β-OHB and fatty acid turnover. g Plasma insulin concentrations. h Liver acetyl-CoA. Data are the mean ± S.E.M., and groups were compared by ANOVA with Bonferroni’s multiple comparisons test